Mod GRF 1-29 (No DAC) (5mg)

What is Mod GRF 1-29 (CJC-1295 No DAC)?

Mod GRF 1-29 is a modified 29-amino-acid fragment of growth-hormone-releasing hormone (GHRH). It is also sold under the name CJC-1295 No DAC. This catalog lists a 5mg vial for in-vitro laboratory research.

Listed vial contents: 5mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

Which identity should I verify?

The catalog also lists CJC-1295 with DAC. The shared naming convention does not make these materials interchangeable. Check the exact sequence, absence of DAC, molecular mass and salt form in an original matching lot document.

What mechanisms are being studied?

Researchers study modified GHRH fragments as signals at the GHRH receptor. This material is listed without the albumin-binding DAC modification. Its identity and behavior must be assessed separately from long-acting CJC-1295 with DAC.

What are the research questions?

• Receptor signaling by a defined modified GHRH fragment
• Differences between DAC-containing and non-DAC constructs
• Sequence verification before comparing published findings

What does the published work describe?

Jetté and colleagues' 2005 paper and Teichman and colleagues' 2006 trials concern long-lasting CJC-1295. They provide context for the DAC construct, not direct validation of this No DAC product. Those findings cannot establish this vial's duration of action, effects or equivalence to the tested material.

What could future research explore?

Future work could compare defined GHRH analogs in the same experimental system. Such comparisons need confirmed sequences and matched study conditions. Possible treatment applications remain separate from the sale of this in-vitro research material.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

The references below explain the identity distinction; they are not direct evidence of benefit for this Mod GRF 1-29 vial. They do not support claims of synergy with another peptide, precise hormone timing or established human safety.

Study references

1. Jetté L, et al. Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PMID 15817669
2. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID 16352683

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.